eicosapentaenoic acid ethyl ester has been researched along with Angina, Unstable in 2 studies
Angina, Unstable: Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gaba, P | 1 |
| Bhatt, DL | 1 |
| Giugliano, RP | 1 |
| Steg, PG | 1 |
| Miller, M | 1 |
| Brinton, EA | 1 |
| Jacobson, TA | 1 |
| Ketchum, SB | 1 |
| Juliano, RA | 1 |
| Jiao, L | 1 |
| Doyle, RT | 1 |
| Granowitz, C | 2 |
| Tardif, JC | 1 |
| Ballantyne, CM | 1 |
| Pinto, DS | 1 |
| Budoff, MJ | 1 |
| Gibson, CM | 1 |
| Wong, ND | 1 |
| Fan, W | 1 |
| Philip, S | 1 |
| Toth, PP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients With Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events With EPA - Intervention Trial)[NCT01492361] | Phase 3 | 8,179 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with a first occurrence of any component of the composite of CV death or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 392 |
| Placebo | 507 |
The primary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), nonfatal stroke, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 705 |
| Placebo | 901 |
The key secondary outcome measure was the number of patients with a first occurrence of any component of the composite of CV death, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 459 |
| Placebo | 606 |
Number of patients with an occurrence of CV death during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 174 |
| Placebo | 213 |
Number of patients with a first occurrence of fatal or nonfatal MI (including silent MI) during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 250 |
| Placebo | 355 |
Number of patients with a first occurrence of fatal or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 98 |
| Placebo | 134 |
Number of patients with a first occurrence of non-elective coronary revascularization represented as the composite of emergent or urgent classifications during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 216 |
| Placebo | 321 |
Number of patients with a first occurrence of any component of the composite of total mortality, nonfatal MI (including silent MI), or nonfatal stroke during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 549 |
| Placebo | 690 |
Number of patients with an occurrence of death from any cause during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 274 |
| Placebo | 310 |
Number of patients with a first occurrence of unstable angina determined to be caused by myocardial ischemia by invasive / non-invasive testing and requiring emergent hospitalization during the follow-up period. (NCT01492361)
Timeframe: Total follow-up time of up to approximately 6 years.
| Intervention | Participants (Count of Participants) |
|---|---|
| AMR101 | 108 |
| Placebo | 157 |
1 trial available for eicosapentaenoic acid ethyl ester and Angina, Unstable
| Article | Year |
|---|---|
Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
Topics: Aged; Angina, Unstable; Eicosapentaenoic Acid; Endpoint Determination; Female; Humans; Hypertriglyce | 2021 |
1 other study available for eicosapentaenoic acid ethyl ester and Angina, Unstable
| Article | Year |
|---|---|
REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
Topics: Aged; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus; Eicosapentaenoic Acid; Eligibili | 2020 |